Countries are at different stages of introducing already approved PrEP, and more PrEP products are coming. Some countries have national programs, others have smaller-scale programs, others aren’t yet offering PrEP at all. In this regularly updated map, yellow countries have some form of PrEP programming; blue countries do not. In this regularly updated map, yellow countries have some form of PrEP programming; blue countries do not.
Want to take the next step in expanding access to PrEP? Check out PrEP Planning A-Z.
This framework outlines the steps involved to introduce oral PrEP as a model for scaling up biomedical HIV prevention products—with links to tools and resources.
Two views of PrEP uptake around the world: The PrEP Tracker as data visualization—a dynamic map exploring global trends
The PrEP Tracker in Excel—details on the full scope of programs in every country
A living document serving as a consolidated map describing current and planned activities at the global level to support ring introduction.
Stories from implementers rolling out PrEP: a look at some real world obstacles and the tools and insights to overcome them.
The US Food and Drug Administration (FDA) approved Apretude, or extended-release cabotegravir, as the first long-acting injectable option for HIV pre-exposure prophylaxis (PrEP).
Nearly a third of people already taking Truvada for PrEP switched to the new combination pill.